Join us for Part 1 of our rural telehealth webinar series, Leveraging Telehealth to Improve Access and Reach in Rural Integrated Care, on Thursday, April 20, 2-3:30 p.m. ET...
SAMHSA is alerting providers and grantees to the risks associated with Xylazine. Xylazine is a non-opioid agent increasingly found in combination with opioids such as fentanyl. This alert offers information regarding the risks posed by Xylazine and to how to prepare to manage patients. The alert by Assistant Secretary for Mental Health and Substance Use, Dr. Miriam E. Delphin-Rittmon, warns that since Xylazine is not an opioid, naloxone does not reverse the effects and severe withdrawal symptoms may occur which are not managed by medications for Opioid Use Disorders. Xylazine may present new potential public health challenges regarding overdose, withdrawal, and severe necrotic skin ulcerations. Click here to view the letter from Dr. Miriam E. Delphin-Rittmon
SAMHSA has issued a report on “Moving Beyond Change Efforts: Evidence and Action to Support and Affirm LGBTQI+ Youth." This report provides behavioral health professionals, researchers, policymakers and other audiences with a comprehensive research overview and accurate information about effective and ineffective therapeutic practices related to youth of diverse sexual orientation and gender identity.
SAMHSA has issued a new advisory on “Cannabidiol (CBD) – Potential Harms, Side Effects, and Unknowns”. This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. The advisory focuses on the risks and harms of CBD, especially those products sold directly to consumers. This advisory also clarifies common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy. It is critical that the general public be made aware of the potential harms associated with CBD use, and parents should keep these products out of the hands of their children.